Compare Sanofi SA (SNY) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.51. The key difference: Sanofi SA pays a 5.5% dividend while iShares Broad USD Investment Grade Corporate Bond pays none, and Sanofi SA is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| SNY | USIG | |
|---|---|---|
Market Cap | $104.83B | — |
Sector | Health | Fixed Income |
52-Week High | $52.34 | $52.69 |
52-Week Low | $41.33 | $50.50 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
